黄素培;张瑞岭;王来海;潘保中;

• 1:新乡医学院第二附属医院

摘要(Abstract)：

目的:介绍抗精神病新药氨磺必利的药理学研究进展与临床应用概况,并评价其疗效,以指导临床正确、合理地个体化选择用药。方法:对近期国内外相关文献进行分析与评价。结果:氨磺必利具有较强的抗精神病作用,低剂量时缓解阴性症状,高剂量时治疗阳性症状,具有较高的临床疗效和较好的耐受性。结论:氨磺必利可作为治疗精神分裂症的一线药物应用于临床。

关键词(KeyWords)： 氨磺必利;精神分裂症;药理学;临床评价

Abstract:

Keywords:

基金项目(Foundation): 河南省卫生科技创新型人才工程(编号:2010-2015)

作者(Authors): 黄素培;张瑞岭;王来海;潘保中;

DOI: 10.14009/j.issn.1672-2124.2011.08.033

参考文献(References)：

• [1]Nuss P,Tessier C.Antipsychotic medication,functionaloutcome and quality of life in schizophrenia:focus onamisulpride[J].Curr Med Res Opion,2010,26(4):787.
• [2]Kerwin R.From pharmacological profiles to clinical outcomes[J].J Int Clin Psychopharmacol,2000,15(4):1.
• [3]Trichard C,Paillere-Martinot ML,Attar-Levy D,et al.Binding of antipsychotic drugs to cortical 5-HT2Areceptors:a PET study of chlorpromazine,clozapine,andamisulpride in schizophrenic patients[J].Am JPsychiatry1,9981,55(4):505.
• [4]Miguel H E,Rogelio A,Ana F,et al.The effects ofamisulpride on five dimensions of psychopathology inpatients with schizophrenia:a prospective open-label study[J].J BMC Psychiatry,2005,5(3):22.
• [5]Kirschbaum KM,Hiemke C,Schmitt U.Rotarodimpairment:catalepsy-like screening test for antipsychoticside effects[J].Int J Neurosci,2009,119(10):1509.
• [6]Masdrakis VG,Papadimitriou GN,Papageorgiou Ce,t al.Development of tardive dyskinesia in a patient takingamisulpride[J].J Prog Neuropsychopharmacol BiolPsychiatry2,0073,1(2):586.
• [7]Fountoulakis KN,Panagiotidis P,Siamouli M,et al,Amisulpride-induced tardive dyskinesia[J].SchizophrRes,2006,88(1-3):232.
• [8]Mendhekar DN,Andrade C.Amisulpride-Induced TardiveDyskinesia and Possible Association of Dyskinesia withHypothyroi-dism[J].J Neuropsychiatry Clin Neurosci,2009,21(1):104.
• [9]Guriz O,Ekinci AE,Orsel S,et al.Amisulpride-inducedtardive dystonia:A case report[J.]Prog Neuropsychos-pharmacol Boil Psychiatry2,0103,4(2):412.
• [10]Goyal N,Sinha VK.Amisulpride-induced tardive dyskinesiain childhood onset Schizophrenia[J].J Pro Neuropsychop-harmacol Boil Psychiatry2,0103,4(4):728.
• [11]Abbas AI,Hedlund PB,Huang XPe,t al.Amisulpride is apotent 5-HT7 antagonist:relevance for antidepressantactions in vivo[J].J Psychopharmacol(Berl),2009,205(1):119.
• [12]Sparshatt A,Taylor D,Patel MX.Amisulpride-dose,plasma concentration,occupancy and response:implicationsfor therapeutic drug monitoring[J].Acta Psychiatr Scand,20091,20(6):416.
• [13]Boter H,Peuskens J,Libiger J,et al.Effectiveness ofantipsychotics in first-episode schizophrenia and schizoph-reniform disorder on response and remission:An openrandomized clinical trial(EUFEST)[J].Schizophr Res,2009,115(2-3):97.
• [14]Komossa K,Rummel-Kluge C,Schwarz S,et al.Olanzapine versus other atypical antipsychotics forschizophrenia[J].Cochrane Database Syst Rev,2010,17(3):CD006654.
• [15]Bhowmick S,Hazra A,Ghost M.Amisulpride versusolanzapine in the treatment of schizophrenia in Indianpatients:randomized controlled trial[J].J Aust N Z JPsychiatry,2010,44(3):237.
• [16]Murphy BP,Stuart AH,Wade D,et al.Efficacy ofamisulpride in treating primary negative symptoms in first-episode psychosis:a pilot study[J].J HumPsychopharmacol,2006,21(8):511.
• [17]Ravizza L.Amisulpride in medium-term treatment ofdysthymia a six-month,double blind safety study versusamitriptyline[J].J Psychopharmacol,1999,13(3):248.
• [18]Smeraldi E.Amisulpride versus fluoxetine in patients withdysthymia or major depression in partial remission:adouble-blind,comparative study[J].J Affect Disord,1998,48(1):47.
• [19]Lecrubier Y,Boyer P,Turjanski S,et al.Amisulprideversus imipramine and placebo in dysthymia and majordepression[J].J Affect Disord,1997,43(2):95.
• [20]Focca P,Fonzo V,Ravizza L,et al.A comparison ofparoxetine and amisulpride in the treatment of dysthymicdisorder[J].J Affect Disord,2002,70(3):313.
• [21]Hardoy MC,Carta MG.Strategy to Accelerate or Augmentthe Antidepressant Response and for An Early Onset ofSSRI Activity.Adjunctive Amisulpride to Fluvoxamine inMajor Depressive Disorder[J].Clin Pract Epidemiol MentHealth,2010,6:1.
• [22]Vieta E,Ros S,Goikolea JM,et al.An open-label study ofamisulpride in the treatment of mania[J].J ClinPsychiatry,2005,66(5):575.
• [23]Croissant B,Hermann D,Olbrich R.Saving potential ofclozapine due to combination with amisulpride[J].Psychopharmakotherapie,2001,8(3):128.
• [24]Lin CC,Bai YM,Wang YC,et al.Improved body weightand metabolic outcomes in overweight or obese psychiatricpatients switched to amisulpride from other atypicalantipsychotics[J].J Clin Psychopharmacol,2009,29(6):529.
• [25]Pelland C,Trudel JF.Atypical antipsychotic efficacy andsafety in managing delirium:a systematic review andcritical analysis[J].J Psychol Neuropsychiatr Vieil,2009,7(2):109.
• [26]Bakhla AK,Goyal N,Nizamie SH.Amisulpride-inducedmania with interictal psychosis[J].J Prog Neuropsychop-harmacol Biol Psychiatry,2009,33(8):1572.
• [27]Akkaya C,Kaya B,Kotan Z,et al.Hyperprolactinemia andpossibly related development of prolactinoma duringamisulpride treatment;three cases[J].J Psychopharmacol,2009,23(6):723.
• [28]Mendhekar DN,Andrade C.Amisulpride-induced tardivedyskinesia and possible association of dyskinesia withhypothyroidism[J].J Neuropsychiatr Clin Neurosci,2009,21(1):104.
• [29]Sevincok L,Balci V,Akyildiz U.Tardive dystoniaassociated with low-dose of amisulpride:a case report[J].J Clin Psychopharmacol,2008,28(5):573.
• [30]Chung AK,Chua SE.Torsade de pointes associated withlow-dose amisulpride:a case report[J].Psychopharmacol,2010,24(3):433.
• [31]Mendhekar D,Lohia D.Urinary incontinence associatedwith amisulpride[J].World J Biol Psychiatry,2009,10(4):1045.
• [32]Abay E,Kose R.Amisulpride-induced neurolepticmalignant syndrome[J].J Neuropsychiatr Clin Neurosci,2007,19(4):488.
• [33]Borras L,Huguelet P.A case report of photosensitivity toamisulpride[J].Prim Care Companion J Clin Psychiatry,2007,9(2):153.
• [34]Harangozo J,Slezak A,Borsos K,et al.Costs of treatmentin patients with schizophrenia switched to amisulpride-one-year follow-up[J].J Psychiatr Hung,2008,23(6):464.
• [35]Nuss P,Tessier C.Antipsychotic medication,functionaloutcome and quality of life in schizophrenia:focus onamisulpride[J].J Curr Med Opin,2010,26(4):787.
• [36]Torta R,Berra C,Binaschi L,et al.Amisulpride in theshort-term treatment of depressive and physical symptomsin cancer patients during chemotherapies[J].SupportCare Cancer,2007,15(5):539.
• [37]Dollfus S,Petit M,Menard JF,et al.Amisulpride versusbromocriptine in infantile autism:a controlled crossovercomparative study of two drugs with opposite effects ondopaminergic function[J].J Autism Dev Disord,1992,22(1):47.
• [38]Kim SW,Shin IS,Kim JM,et al.Amisulpride improves obsessive-compulsive symptoms in schizophrenia patientstaking atypical antipsychotics:an open-label switch study[J].J Clin Psychopharmacol,2008,28(3):349.
• [39]Isbister GK,Balit CR,Macleod D,et al.Amisulpride Overdose Is Frequently Associated With QT Prolongationand Torsades de Pointe[J].J Clin Psychopharmacol,2010,30(4):1.